The first experience of immunotherapy application of ipilimumab in combination with chemotherapy of small-cell lung cancer in the Russian population. Analysis of the combined data of two centers, participating in the multicenter randomized phase III study СА 184-156

Introduction. Patients with advanced small cell lung cancer (SCLC) have an extremely poor prognosis on the background of standard chemotherapy combination of etoposide and platinum-based drugs. In a randomized, double-blind of СА184-156 phase III study, the efficacy and safety of ipilimumab (immune...

Full description

Bibliographic Details
Main Authors: A E Kuzminov, V A Gorbunova, E V Poddubskaya, S G Bagrova, M P Baranova, K K Laktionov
Format: Article
Language:Russian
Published: IP Habib O.N. 2018-09-01
Series:Современная онкология
Subjects:
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/29557/pdf